PL1899334T3 - Związki naftyrydynowe - Google Patents

Związki naftyrydynowe

Info

Publication number
PL1899334T3
PL1899334T3 PL06773519T PL06773519T PL1899334T3 PL 1899334 T3 PL1899334 T3 PL 1899334T3 PL 06773519 T PL06773519 T PL 06773519T PL 06773519 T PL06773519 T PL 06773519T PL 1899334 T3 PL1899334 T3 PL 1899334T3
Authority
PL
Poland
Prior art keywords
sub
naphthyridine compounds
histamine
receptor
serotonin
Prior art date
Application number
PL06773519T
Other languages
English (en)
Inventor
Michael A Letavic
John M Keith
Nicholas I Carruthers
Chandravadan R Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL1899334T3 publication Critical patent/PL1899334T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL06773519T 2005-06-17 2006-06-16 Związki naftyrydynowe PL1899334T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69200305P 2005-06-17 2005-06-17
EP06773519A EP1899334B1 (en) 2005-06-17 2006-06-16 Naphthyridine compounds
PCT/US2006/023788 WO2006138714A2 (en) 2005-06-17 2006-06-16 Naphthyridine compounds

Publications (1)

Publication Number Publication Date
PL1899334T3 true PL1899334T3 (pl) 2009-04-30

Family

ID=37263777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06773519T PL1899334T3 (pl) 2005-06-17 2006-06-16 Związki naftyrydynowe

Country Status (14)

Country Link
US (1) US7417054B2 (pl)
EP (1) EP1899334B1 (pl)
JP (1) JP2008543880A (pl)
CN (1) CN101243083A (pl)
AT (1) ATE409188T1 (pl)
AU (1) AU2006261162A1 (pl)
CA (1) CA2612409A1 (pl)
DE (1) DE602006002894D1 (pl)
DK (1) DK1899334T3 (pl)
ES (1) ES2314933T3 (pl)
PL (1) PL1899334T3 (pl)
PT (1) PT1899334E (pl)
SI (1) SI1899334T1 (pl)
WO (1) WO2006138714A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
ATE420881T1 (de) * 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
CA2612495A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2656075A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
WO2008002818A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted aminomethyl benzamide compounds
CA2656089A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008064036A1 (en) * 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators
AU2008223145A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine H3 receptor
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
CA2719985A1 (en) * 2008-03-31 2009-10-08 Evotec Ag Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
JP5364327B2 (ja) * 2008-09-26 2013-12-11 富士フイルム株式会社 ハロピラジンカルボキサミド化合物の製造方法
CN113024456B (zh) * 2021-02-23 2022-05-13 江苏先导药业有限公司 一种2-氯烟酸的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH527194A (de) 1970-01-06 1972-08-31 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
GB1558043A (en) * 1976-02-03 1979-12-19 Onoda Cement Co Ltd Metal squeeze out tube and method and apparatus for forming a powder layer on its surface
PT831829E (pt) * 1995-06-07 2003-12-31 Pfizer Derivados de pirimidina heterociclicos de aneis fundidos
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
NZ519146A (en) 1999-11-03 2004-02-27 Albany Molecular Res Inc 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
JP2008524252A (ja) 2004-12-17 2008-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｎｓ障害の処置のためのテトラヒドロイソキノリン化合物

Also Published As

Publication number Publication date
SI1899334T1 (sl) 2009-04-30
JP2008543880A (ja) 2008-12-04
DK1899334T3 (da) 2008-11-24
US20060287292A1 (en) 2006-12-21
PT1899334E (pt) 2008-11-06
EP1899334B1 (en) 2008-09-24
CN101243083A (zh) 2008-08-13
AU2006261162A1 (en) 2006-12-28
US7417054B2 (en) 2008-08-26
WO2006138714A2 (en) 2006-12-28
ATE409188T1 (de) 2008-10-15
ES2314933T3 (es) 2009-03-16
EP1899334A2 (en) 2008-03-19
DE602006002894D1 (de) 2008-11-06
WO2006138714A3 (en) 2007-03-15
CA2612409A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
PT1899334E (pt) Compostos de naftiridina
HK1118550A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
WO2008002820A3 (en) Substituted benzyl amine compounds
IL189164A0 (en) Pyrimidine compounds as serotonin receptor modulators
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
MY145305A (en) Cyclopropyl amines as modulators of the histamine h3 receptor
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
GB0416508D0 (en) Therapeutic agents
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
TW200510398A (en) Novel compounds
MXPA05013478A (es) Combinaciones terapeuticas.
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
UA85563C2 (ru) Конденсированные гетероциклические соединения
GB0508988D0 (en) Organic compounds
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.
TW200744607A (en) Pyrimidine compounds as serotonin receptor modulators
MY145145A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators